SPRO News and Press, Spero Therapeutics Inc.

WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer. “We are delighted to welcome K...

2026-06-18 15:41:04 ET Investment Overview - Background To Yesterday's FDA Approval For Utebzi The stock of Spero Therapeutics, Inc. ( SPRO ), a Cambridge, Massachusetts-based biotech, showed volatility yesterday in response to the news announced by the company that: ...

2026-06-18 10:29:28 ET DENVER, Colo. ( 247marketnews.com ) --The healthcare and biotechnology sector continues to generate a steady stream of meaningful catalysts as companies advance novel therapies, secure regulatory milestones, strengthen intellectual property portfolios, and expand ...

2026-06-18 06:02:33 ET More on related tickers, etc. Smith & Wesson Brands, Inc. (SWBI) Q4 2026 Earnings Call Transcript Intel: The Re-Rating Has Gone Too Far Smith & Wesson: It's Time To Pull The Trigger On A Downgrade Trump: Apple agrees to work wit...

A look at the top 10 most actives in the United States Aditxt Inc. (ADTX) fell 59.6% to $0.0044 on volume of 1,041,656,608 shares Sleep Number Corporation (SNBR) rose 120.8% to $0.39 on volume of 895,409,856 shares Direxion Daily Semiconductor Bear 3X (SOXS) fell 3.7% to $4.46 on volume of ...

First and only oral carbapenem antibiotic approved in the US Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment i More than 3 million cases of cUTIs are treated annually in the US with a third of patients impacted by resistant infections ii...

2026-06-17 11:30:32 ET More on GSK Nuvalent: 'Hold' On GlaxoSmithKline Acquisition For Selective Tyrosine Kinase Inhibitors GSK plc (GSK) M&A Call Transcript GSK plc (GSK) Nuvalent, Inc. - M&A Call - Slideshow Key deals this week: GSK, Incyte, Ingredi...

2026-06-12 15:00:02 ET More on the markets Token Spending Crashes: AI In Trouble? SpaceX Debut Likely Marks An Intermediate Top We May Have Peace In The Middle East But High Inflation Is Here To Stay Rebuilding the tariff wall with Section 301 BofA wa...

2026-06-08 09:59:54 ET Initiating Coverage at Hold Rating I initiate coverage of Spero Therapeutics ( SPRO ) with a Hold rating. I believe SPRO offers a clean but highly concentrated investment set-up, with too much reliance on their lead near commercial asset, tebipenem ...

New Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), including pyelonephritis, is under review at the FDA, with PDUFA date of June 18, 2026 Spero maintains its cash runway guidance into 2028 CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Spero...